Literature DB >> 9218932

Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole.

S Jaruratanasirikul1, A Kleepkaew.   

Abstract

OBJECTIVE: To evaluate the effectiveness of Coca-Cola in enhancing the absorption of itraconazole.
METHODS: Eight healthy volunteers were randomized to receive two treatment sequences in a two-way crossover design with a 1-week wash-out period separating each study treatment. Treatment 1, the control, consisted of 100 mg itraconazole with 325 ml water. Treatment II was identical to treatment I, except that itraconazole was administered with 325 ml of Coca-Cola (pH 2.5).
RESULTS: Serum itraconazole concentrations, after administration with Coca-Cola (treatment II), were higher than after administration with water (treatment I). The mean AUC was 1.12 vs 2.02 micrograms.h.m1-1, the mean Cmax was 0.14 vs 0.31 micrograms.m1-1 and the mean tmax was 2.56 vs 3.38 h in treatments I and II, respectively.
CONCLUSION: The absorption of itraconazole can be enhanced by Coca-Cola.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9218932     DOI: 10.1007/s002280050280

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

Review 1.  Role of itraconazole in haematology/oncology.

Authors:  N A Pandya; A A Atra; U Riley; C R Pinkerton
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

Review 2.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients.

Authors:  Timothy H Waterhouse; Stefanie Redmann; Stephen B Duffull; John A Eccleston
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

4.  A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients.

Authors:  Stefanie Hennig; Timothy H Waterhouse; Scott C Bell; Megan France; Claire E Wainwright; Hugh Miller; Bruce G Charles; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2006-10-30       Impact factor: 4.335

Review 5.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

6.  What is the role of therapeutic drug monitoring in antifungal therapy?

Authors:  Jeannina A Smith
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

7.  Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.

Authors:  Stefanie Hennig; Claire E Wainwright; Scott C Bell; Hugh Miller; Lena E Friberg; Bruce G Charles
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.

Authors:  Gopal Krishna; Allen Moton; Lei Ma; Matthew M Medlock; James McLeod
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 9.  Endemic Mycoses in Solid Organ Transplant Recipients.

Authors:  Jeremy S Nel; Luther A Bartelt; David van Duin; Anne M Lachiewicz
Journal:  Infect Dis Clin North Am       Date:  2018-09       Impact factor: 5.982

Review 10.  Optimisation of itraconazole therapy using target drug concentrations.

Authors:  J M Poirier; G Cheymol
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.